Degradation of Phage Transcripts by CRISPR-Associated RNases Enables Type III CRISPR-Cas Immunity

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2016 Feb 9

PMID 26853474

Citations 115

Authors

Wenyan Jiang

Poulami Samai

Luciano A Marraffini

Affiliations

Soon will be listed here.

Abstract

Type III-A CRISPR-Cas systems defend prokaryotes against viral infection using CRISPR RNA (crRNA)-guided nucleases that perform co-transcriptional cleavage of the viral target DNA and its transcripts. Whereas DNA cleavage is essential for immunity, the function of RNA targeting is unknown. Here, we show that transcription-dependent targeting results in a sharp increase of viral genomes in the host cell when the target is located in a late-expressed phage gene. In this targeting condition, mutations in the active sites of the type III-A RNases Csm3 and Csm6 lead to the accumulation of the target phage mRNA and abrogate immunity. Csm6 is also required to provide defense in the presence of mutated phage targets, when DNA cleavage efficiency is reduced. Our results show that the degradation of phage transcripts by CRISPR-associated RNases ensures robust immunity in situations that lead to a slow clearance of the target DNA.

Citing Articles

Mechanistic determinants and dynamics of cA6 synthesis in type III CRISPR-Cas effector complexes.

Jungfer K, Moravcik S, Garcia-Doval C, Knorlein A, Hall J, Jinek M Nucleic Acids Res. 2025; 53(2).

PMID: 39817514 PMC: 11734703. DOI: 10.1093/nar/gkae1277.

Engineering Phages to Fight Multidrug-Resistant Bacteria.

Peng H, Chen I, Qimron U Chem Rev. 2024; 125(2):933-971.

PMID: 39680919 PMC: 11758799. DOI: 10.1021/acs.chemrev.4c00681.

CRISPR-based gene editing technology and its application in microbial engineering.

Wei J, Li Y Eng Microbiol. 2024; 3(4):100101.

PMID: 39628916 PMC: 11610974. DOI: 10.1016/j.engmic.2023.100101.

Cas10 relieves host growth arrest to facilitate spacer retention during type III-A CRISPR-Cas immunity.

Aviram N, Shilton A, Lyn N, Reis B, Brivanlou A, Marraffini L Cell Host Microbe. 2024; 32(12):2050-2062.e6.

PMID: 39626678 PMC: 11708336. DOI: 10.1016/j.chom.2024.11.005.

Engineered transcription-associated Cas9 targeting in eukaryotic cells.

Goldberg G, Kogenaru M, Keegan S, Haase M, Kagermazova L, Arias M Nat Commun. 2024; 15(1):10287.

PMID: 39604381 PMC: 11603292. DOI: 10.1038/s41467-024-54629-9.

References

Hale C, Cocozaki A, Li H, Terns R, Terns M . Target RNA capture and cleavage by the Cmr type III-B CRISPR-Cas effector complex. Genes Dev. 2014; 28(21):2432-43. PMC: 4215187. DOI: 10.1101/gad.250712.114. View

Weinberger A, Wolf Y, Lobkovsky A, Gilmore M, Koonin E . Viral diversity threshold for adaptive immunity in prokaryotes. mBio. 2012; 3(6):e00456-12. PMC: 3517865. DOI: 10.1128/mBio.00456-12. View

Tamulaitis G, Kazlauskiene M, Manakova E, Venclovas C, Nwokeoji A, Dickman M . Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus. Mol Cell. 2014; 56(4):506-17. DOI: 10.1016/j.molcel.2014.09.027. View

Ramia N, Spilman M, Tang L, Shao Y, Elmore J, Hale C . Essential structural and functional roles of the Cmr4 subunit in RNA cleavage by the Cmr CRISPR-Cas complex. Cell Rep. 2014; 9(5):1610-1617. PMC: 4269474. DOI: 10.1016/j.celrep.2014.11.007. View

Peng W, Feng M, Feng X, Liang Y, She Q . An archaeal CRISPR type III-B system exhibiting distinctive RNA targeting features and mediating dual RNA and DNA interference. Nucleic Acids Res. 2014; 43(1):406-17. PMC: 4288192. DOI: 10.1093/nar/gku1302. View

Nunez J, Lee A, Engelman A, Doudna J . Integrase-mediated spacer acquisition during CRISPR-Cas adaptive immunity. Nature. 2015; 519(7542):193-8. PMC: 4359072. DOI: 10.1038/nature14237. View

Heler R, Samai P, Modell J, Weiner C, Goldberg G, Bikard D . Cas9 specifies functional viral targets during CRISPR-Cas adaptation. Nature. 2015; 519(7542):199-202. PMC: 4385744. DOI: 10.1038/nature14245. View

Koonin E, Krupovic M, Yutin N . Evolution of double-stranded DNA viruses of eukaryotes: from bacteriophages to transposons to giant viruses. Ann N Y Acad Sci. 2015; 1341:10-24. PMC: 4405056. DOI: 10.1111/nyas.12728. View

Samai P, Pyenson N, Jiang W, Goldberg G, Hatoum-Aslan A, Marraffini L . Co-transcriptional DNA and RNA Cleavage during Type III CRISPR-Cas Immunity. Cell. 2015; 161(5):1164-1174. PMC: 4594840. DOI: 10.1016/j.cell.2015.04.027. View

10.

Weinberger A, Gilmore M . A CRISPR View of Cleavage. Cell. 2015; 161(5):964-966. DOI: 10.1016/j.cell.2015.05.003. View

11.

Makarova K, Wolf Y, Alkhnbashi O, Costa F, Shah S, Saunders S . An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015; 13(11):722-36. PMC: 5426118. DOI: 10.1038/nrmicro3569. View

12.

Kreiswirth B, Lofdahl S, Betley M, OReilly M, Schlievert P, Bergdoll M . The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature. 1983; 305(5936):709-12. DOI: 10.1038/305709a0. View

13.

Pourcel C, Salvignol G, Vergnaud G . CRISPR elements in Yersinia pestis acquire new repeats by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary studies. Microbiology (Reading). 2005; 151(Pt 3):653-663. DOI: 10.1099/mic.0.27437-0. View

14.

Hatoum-Aslan A, Maniv I, Samai P, Marraffini L . Genetic characterization of antiplasmid immunity through a type III-A CRISPR-Cas system. J Bacteriol. 2013; 196(2):310-7. PMC: 3911255. DOI: 10.1128/JB.01130-13. View

15.

Nunez J, Kranzusch P, Noeske J, Wright A, Davies C, Doudna J . Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-Cas adaptive immunity. Nat Struct Mol Biol. 2014; 21(6):528-34. PMC: 4075942. DOI: 10.1038/nsmb.2820. View

16.

Heler R, Marraffini L, Bikard D . Adapting to new threats: the generation of memory by CRISPR-Cas immune systems. Mol Microbiol. 2014; 93(1):1-9. PMC: 4104294. DOI: 10.1111/mmi.12640. View

17.

Arslan Z, Hermanns V, Wurm R, Wagner R, Pul U . Detection and characterization of spacer integration intermediates in type I-E CRISPR-Cas system. Nucleic Acids Res. 2014; 42(12):7884-93. PMC: 4081107. DOI: 10.1093/nar/gku510. View

18.

Benda C, Ebert J, Scheltema R, Schiller H, Baumgartner M, Bonneau F . Structural model of a CRISPR RNA-silencing complex reveals the RNA-target cleavage activity in Cmr4. Mol Cell. 2014; 56(1):43-54. DOI: 10.1016/j.molcel.2014.09.002. View

19.

Goldberg G, Jiang W, Bikard D, Marraffini L . Conditional tolerance of temperate phages via transcription-dependent CRISPR-Cas targeting. Nature. 2014; 514(7524):633-7. PMC: 4214910. DOI: 10.1038/nature13637. View

20.

Garneau J, Dupuis M, Villion M, Romero D, Barrangou R, Boyaval P . The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010; 468(7320):67-71. DOI: 10.1038/nature09523. View